TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11818761

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the lateralization control point (10-mA current, 299 Hz on dominant side, 149 Hz on contralateral side)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no electrical stimulation)
Number of subjects: 20
Study: 10406365

Group type: EXPERIMENTAL
Intervention: Better pain treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pain control
Number of subjects: 0
Study: 2135070

Group type: EXPERIMENTAL
Intervention: Pyritinol 600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pyritinol 1200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 378623

Group type: EXPERIMENTAL
Intervention: Oral L-dopa 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 0
Study: 31155223

Group type: EXPERIMENTAL
Intervention: Intervention website (I-DECIDE)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control website (static intimate partner violence information website)
Number of subjects: 422
Study: 27091596

Group type: EXPERIMENTAL
Intervention: 1% Alendronate (ALN) gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1.2% Atorvastatin (ATV) gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study: 24820545

Group type: EXPERIMENTAL
Intervention: Repetition-lag training
Number of subjects: 31

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 31
Study: 22996024

Group type: EXPERIMENTAL
Intervention: AET/RET 1 × wk
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: AET/RET 2 × wk
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: AET/RET 3 × wk
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study: 21343762

Group type: EXPERIMENTAL
Intervention: Labor epidural analgesia
Number of subjects: 200
Study: 19712124

Group type: EXPERIMENTAL
Intervention: Individualized assessment and treatment program (IATP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Comprehensive packaged CBT program (PCBT)
Number of subjects: 110
Study: 17387131

Group type: EXPERIMENTAL
Intervention: Atorvastatin combined with 60 mg of torcetrapib for 2 years
Number of subjects: 850

Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 850
Study: 15492573

Group type: EXPERIMENTAL
Intervention: 40 mL/kg intraoperative administration of lactated Ringer's solution (LR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 15 mL/kg intraoperative administration of lactated Ringer's solution (LR)
Number of subjects: 48
Study: 11446476

Group type: EXPERIMENTAL
Intervention: Enoxaparin 2,500 IU once daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard Heparin 5,000 IU three times daily
Number of subjects: 102
Study: 9572995

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 400 microg/m2 IV over 30 minutes once daily
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 234
Study: 8071389

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 4 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Temazepam (10 mg single oral dose)
Number of subjects: 21
Study: 3342282

Group type: EXPERIMENTAL
Intervention: Liquid formulation of benzydamine hydrochloride with ICEBERG AR 84/05/15 flavoring agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liquid formulation of benzydamine hydrochloride without ICEBERG AR 84/05/15 flavoring agent
Number of subjects: 0
Study: 31882376

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, with dose increase to 150 mg every 2 weeks at week 12 if week 8 LDL-C was >1.81 mmol/L)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 615

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 615
Study: 29266308

Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg once daily
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: PF-06700841 100 mg once daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: PF-06700841 (various doses)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 28394215

Group type: EXPERIMENTAL
Intervention: Exergame program (30 minutes per week for 2 weeks)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (no exergame intervention)
Number of subjects: 337
Study: 25119580

Group type: EXPERIMENTAL
Intervention: Placebo treatment with warning about side effects
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Placebo treatment without warning about side effects
Number of subjects: 91

Group type: COMPARATOR
Intervention: No treatment with warning about side effects
Number of subjects: 91

Group type: COMPARATOR
Intervention: No treatment without warning about side effects
Number of subjects: 91
Study: 23672267

Group type: EXPERIMENTAL
Intervention: rhANP 0.1 μg/kg/min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: rhANP 0.2 μg/kg/min
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: rhANP 0.05 μg/kg/min
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 48
Study: 20439384

Group type: EXPERIMENTAL
Intervention: School-based nurse-directed smokeless tobacco cessation intervention including peer-led educational sessions and oral exams by the school nurse with brief tobacco cessation counseling.
Number of subjects: 4731

Group type: COMPARATOR
Intervention: No-intervention group (control).
Number of subjects: 4731

Group type: EXPERIMENTAL
Intervention: Baseline nonsmoking ST users.
Number of subjects: 4731
Study: 18520292

Group type: EXPERIMENTAL
Intervention: Bevacizumab at 15 mg/kg every 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab at 7.5 or 15 mg/kg every 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine
Number of subjects: 0
Study: 16176312

Group type: EXPERIMENTAL
Intervention: Mainstem method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Marker method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Formula method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Marker method (age-stratified 3-12 months)
Number of subjects: 60
Study: 12687554

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) continued for >300 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Alendronate (ALN) discontinued (<90 days of therapy)
Number of subjects: 90
Study: 10400478

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg twice daily)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) (84 microg four times daily)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 386
Study: 8911782

Group type: EXPERIMENTAL
Intervention: Purified micronized flavonoid fraction (Daflon 500 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1868678

Group type: EXPERIMENTAL
Intervention: ciprofloxacin (750 mg every 12 hours for five doses)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: temafloxacin (600 mg every 12 hours for five doses)
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo (given every 12 hours for five doses)
Number of subjects: 13
Study: 6109798

Group type: EXPERIMENTAL
Intervention: Low Na diet supplemented with potassium for 2 weeks (low Na/high K)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High Na diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low Na diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low Na diet supplemented with potassium (low Na/high K)
Number of subjects: 0
Study: 30326264

Group type: COMPARATOR
Intervention: Vicagrel 5 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Vicagrel 20 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vicagrel 25 mg
Number of subjects: 79
Study: 29116990

Group type: EXPERIMENTAL
Intervention: Higher physical activity levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fewer symptoms of depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less stress and/or anxiety (decreased mood)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less back pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stronger social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reports of low work demands
Number of subjects: 0
Study: 25888657

Group type: EXPERIMENTAL
Intervention: Faded feedback group (HRV biofeedback with reduced feedback over sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Full feedback group (continuous HRV biofeedback)
Number of subjects: 20
Study: 23962220

Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 700
Study: 20609136

Group type: EXPERIMENTAL
Intervention: Specific IgE for food items
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Specific IgE for beef
Number of subjects: 85
Study: 19497707

Group type: EXPERIMENTAL
Intervention: DCD-training group (table-tennis training program, 10 weeks, 3 times a week)
Number of subjects: 27

Group type: COMPARATOR
Intervention: DCD non-training group
Number of subjects: 27
Study: 16715780

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15612841

Group type: EXPERIMENTAL
Intervention: PREP delivered by university clinicians (U-PREP)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: PREP delivered by RO clergy (RO-PREP)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Naturally occurring (NO) marriage preparation
Number of subjects: 217
Study: 11352439

Group type: EXPERIMENTAL
Intervention: Calcium 500mg (Calcium‐Sandoz Forte) administered before, and 12 and 24 hours after moxifloxacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Moxifloxacin 400mg without calcium
Number of subjects: 12
Study: 9164427

Group type: EXPERIMENTAL
Intervention: buspirone 30 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 8220803

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms once daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms once daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 3121343

Group type: EXPERIMENTAL
Intervention: Lipofundin MCT (10%)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intralipid (10%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Lipofundin S (10%)
Number of subjects: 6
Study: 30285715

Group type: EXPERIMENTAL
Intervention: Condition A: Only one audience member present
Number of subjects: 49

Group type: COMPARATOR
Intervention: Condition B: Presence of an audience of 5 health care providers
Number of subjects: 49
Study: 26285691

Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metoprolol succinate 100 mg daily
Number of subjects: 19
Study: 25002002

Group type: EXPERIMENTAL
Intervention: Visit-independent population management IT application involving PCPs
Number of subjects: 103870

Group type: COMPARATOR
Intervention: Automated reminder system
Number of subjects: 103870
Study: 22911615

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DRZ)
Number of subjects: 255

Group type: COMPARATOR
Intervention: No dexrazoxane
Number of subjects: 255
Study: 20555272

Group type: EXPERIMENTAL
Intervention: Uniaxial unstable surface balance training on a rocker board (RB)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiaxial unstable surface balance training on a dynadisc (DD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined treatment groups (DD and RB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups combined (CON + DD + RB)
Number of subjects: 36
Study: 17585663

Group type: EXPERIMENTAL
Intervention: Point-through-point electroacupuncture (EA)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non point-through-point group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Western medicine group
Number of subjects: 108
Study: 15065482

Group type: EXPERIMENTAL
Intervention: Component parts of pulmonary rehabilitation
Number of subjects: 0
Study: 11811810

Group type: EXPERIMENTAL
Intervention: Individualized music
Number of subjects: 4

Group type: COMPARATOR
Intervention: Classical music
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control period without music
Number of subjects: 4
Study: 9625841

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy in NSCLC (14 patients)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy in SCLC (9 patients)
Number of subjects: 23
Study: 7939505

Group type: EXPERIMENTAL
Intervention: Thoracotomy in cirrhotic patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (normal liver function)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Management of significant pleural effusions in cirrhotic patients
Number of subjects: 11
Study: 3286783

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg) every 12 hours for 28 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28553835

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27429397

Group type: EXPERIMENTAL
Intervention: 1 other person present during simulation
Number of subjects: 70

Group type: COMPARATOR
Intervention: 3 other people present during simulation
Number of subjects: 70
Study: 24650839

Group type: EXPERIMENTAL
Intervention: Web-based dietitian-led (WD) team care intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 101
Study: 22940254

Group type: EXPERIMENTAL
Intervention: Herbal medicines only (57 patients)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Herbal and conventional medicines concurrently (256 patients)
Number of subjects: 313
Study: 20729255

Group type: EXPERIMENTAL
Intervention: Synbiotic preparation (Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and fructooligosaccharide)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Synbiotic preparation
Number of subjects: 135
Study: 18685795

Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 15671472

Group type: EXPERIMENTAL
Intervention: 3-session intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 15576257

Group type: EXPERIMENTAL
Intervention: 6-month, 3 times per week, leader-led walking group activity (n = 28)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Information-only control group (n = 28)
Number of subjects: 582
Study: 11719721

Group type: EXPERIMENTAL
Intervention: Telephone follow-up discussions
Number of subjects: 185

Group type: COMPARATOR
Intervention: Appointment follow-ups
Number of subjects: 185
Study: 9594263

Group type: EXPERIMENTAL
Intervention: Atenolol (group A)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Enalapril (group E)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Atenolol and Enalapril
Number of subjects: 1106
Study: 8201563

Group type: EXPERIMENTAL
Intervention: Aspirated Viscoat (30 eyes)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Retained Viscoat (30 eyes)
Number of subjects: 55
Study: 2852948

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin and etoposide)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Radiotherapy of the thorax
Number of subjects: 101
Study: 31880479

Group type: EXPERIMENTAL
Intervention: Continuation of treatment with 36 or 54 mg extended release methylphenidate for 7 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Gradual withdrawal over 3 to 4 weeks placebo
Number of subjects: 94
Study: 31567676

Group type: EXPERIMENTAL
Intervention: Pectoralis major tendon transfer (PMT)
Number of subjects: 28
Study: 28627070

Group type: EXPERIMENTAL
Intervention: Hydrolysed wheat flour (10 g of gluten/d for 3 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Natural wheat flour (10 g of gluten/d for 3 days)
Number of subjects: 20
Study: 26545731

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Play therapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination of Entonox and play therapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Existing standard interventions (Control)
Number of subjects: 123
Study: 23404916

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (cuff deflated)
Number of subjects: 149
Study: 21216860

Group type: EXPERIMENTAL
Intervention: Automated bio-behavioral feedback (levels 1-2-3 or 2-3-1)
Number of subjects: 120
Study: 17435692

Group type: EXPERIMENTAL
Intervention: 25 mg intravitreal triamcinolone acetonide injection
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (fellow eyes)
Number of subjects: 38
Study: 16442667

Group type: EXPERIMENTAL
Intervention: Gain-framed nutrition message (positive benefits of eating apples)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Loss-framed nutrition message (negative consequences of not eating apples)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control scene (children playing a game)
Number of subjects: 50
Study: 14518703

Group type: EXPERIMENTAL
Intervention: Once-a-day regimen (EFV+ddl+3TC)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Twice-a-day low-pill burden regimen (EFV+Combivir)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Twice-a-day high-pill burden regimen (NFV+Combivir)
Number of subjects: 102
Study: 10606833

Group type: EXPERIMENTAL
Intervention: Inhaled rac-salbutamol (1200 microg) with oral charcoal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intravenous rac-salbutamol (500 microg)
Number of subjects: 15
Study: 9083592

Group type: EXPERIMENTAL
Intervention: Didactic lecture format
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm presentation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Color slide photographic demonstration
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bedside teaching rounds
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Meet-the-professor sessions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Overall instructional methods
Number of subjects: 57
Study: 8248391

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lunch consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extraversion vs. Introversion in sleep-deprived subjects
Number of subjects: 0
Study: 2868579

Group type: EXPERIMENTAL
Intervention: i.v. famotidine 10 mg every 6-12 hours for maximally seven days
Number of subjects: 20

Group type: COMPARATOR
Intervention: i.v. ranitidine every 6-12 hours for maximally seven days
Number of subjects: 20
Study: 31146740

Group type: EXPERIMENTAL
Intervention: MCT oil supplement (9% metabolic energy based calculated)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control dietary supplement (DS)
Number of subjects: 36
Study: 28077059

Group type: EXPERIMENTAL
Intervention: 12-hour course on the Danish healthcare system
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Written information on the Danish healthcare system
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1158
Study: 26455674

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT) consisting of 6 individual sessions
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 90
Study: 23876862

Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACE)
Number of subjects: 180
Study: 21393398

Group type: EXPERIMENTAL
Intervention: Simulated obstructive hypopnea (inspiration through threshold load)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Müller maneuver (simulated obstructive apnea)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: End‐expiratory central apnea
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Release of threshold load inspiration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Release of Müller maneuver
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Release of end‐expiratory central apnea
Number of subjects: 20
Study: 18982437

Group type: EXPERIMENTAL
Intervention: 3-week oral anticoagulation therapy (OACs) before heparin bridging
Number of subjects: 188

Group type: COMPARATOR
Intervention: No prior oral anticoagulation therapy (N-OACs)
Number of subjects: 188
Study: 17237480

Group type: EXPERIMENTAL
Intervention: Haemodiafiltration with online regeneration of ultrafiltrate (HFR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-flux bicarbonate dialysis (HD)
Number of subjects: 14
Study: 14971670

Group type: EXPERIMENTAL
Intervention: Adrenaline and saline infiltration (2.5 mg of 1:1000 adrenaline diluted in 500 mL of normal saline)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Tourniquet and postoperative drain
Number of subjects: 115
Study: 11167277

Group type: EXPERIMENTAL
Intervention: Latanoprost once daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Timolol plus dorzolamide twice daily
Number of subjects: 35
Study: 9693996

Group type: EXPERIMENTAL
Intervention: Panic disorder patients
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Panic disorder patients and normal controls
Number of subjects: 53